- Imara Inc (NASDAQ:IMRA) has agreed to divest tovinontrine (IMR-687) and all other assets related to its PDE9 program to Cardurion Pharmaceuticals Inc.
- In addition to $250,000 previously paid by Cardurion upon execution of a non-binding term sheet, the aggregate purchase price consists of an upfront payment of $34.75 million and $60 million as milestone payments.
- In case of termination, the company would be obligated to pay a fee of $1.5 million Cardurion.
- In April, Imara posted interim analyses of its Ardent Phase 2b trial of tovinontrine (IMR-687) in sickle cell disease (SCD) and Forte Phase 2b trial in beta-thalassemia.
- No meaningful benefit was observed in transfusion burden in either tovinontrine group compared to the placebo in the beta-thalassemia study.
- Imara announced discontinuing the Ardent and Forte trials and further developing tovinontrine in sickle cell disease and beta-thalassemia.
- Price Action: IMRA shares are up 37.60% at $1.61 during the premarket session on the last check Wednesday.
‘Dogecoin Killer’ Shiba Inu Drops 12% In 7 Days, But ‘It’s Not Done Yet,’ Says Trader
‘Dogecoin Killer' Shiba Inu's (CRYPTO: SHIB) recent price drop did not stop traders from remaining optimistic about the meme coin. Positive community developments cushion the meme coin's price.
